Alterity Therapeutics (ATHE) Operating Leases (2019 - 2025)

Alterity Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $56707.2 for Q2 2025.

• On a quarterly basis, Operating Leases rose 65.75% year-over-year to $56707.2 in Q2 2025; TTM through Jun 2025 was $56707.2, a 65.75% increase from a year earlier, with the FY2025 full-year figure at $56707.2, up 65.75% from the prior year.
• Operating Leases improved to $56707.2 in Q2 2025 per ATHE's latest filing, from $34212.6 in the prior quarter.
• Across five years, Operating Leases topped out at $68979.5 in Q2 2023 and bottomed at $29187.4 in Q2 2021.
• The 5-year median for Operating Leases is $42873.7 (2022), against an average of $46392.1.
• Across the five-year window, Operating Leases slumped 50.4% in 2024 and surged 65.75% in 2025, its largest moves.
• Year by year, Operating Leases stood at $29187.4 in 2021, then jumped by 46.89% to $42873.7 in 2022, then surged by 60.89% to $68979.5 in 2023, then slumped by 50.4% to $34212.6 in 2024, then jumped by 65.75% to $56707.2 in 2025.
• Per Business Quant, the three latest ATHE Operating Leases figures stand at $56707.2 (Q2 2025), $34212.6 (Q2 2024), and $68979.5 (Q2 2023).